Lineage Cell Therapeutics (LCTX) FCF Margin Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15,064.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 723.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1,409.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | 610.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 610.00 |
| Dec 31, 2025 | 33,130.00 |
| Sep 30, 2025 | 9,643.00 |
| Jun 30, 2025 | -4,359.00 |
| Mar 31, 2025 | -74,913.00 |
| Dec 31, 2024 | -22,855.00 |
| Sep 30, 2024 | 6,485.00 |
| Jun 30, 2024 | 71,184.00 |
| Mar 31, 2024 | 149,842.00 |
| Dec 31, 2023 | 130,315.00 |
| Sep 30, 2023 | 43,766.00 |
| Jun 30, 2023 | 89,636.00 |
| Mar 31, 2023 | 50,219.00 |
| Dec 31, 2022 | 3,297.00 |
| Sep 30, 2022 | 113,254.00 |
| Jun 30, 2022 | 110,875.00 |
| Mar 31, 2022 | 143,925.00 |
| Dec 31, 2021 | 81,540.00 |
| Sep 30, 2021 | 54,719.00 |
| Jun 30, 2021 | -79,094.00 |